Psychiatry
VistaGen’s horizons may shrink after clinical trial setback
Phil Taylor
central nervous system, Psychiatry, social anxiety disorder, VistaGen Therapeutics
0 Comment
AbbVie adds to Vraylar data as FDA considers depression use
Phil Taylor
AbbVie, depression, Psychiatry, Vraylar
0 Comment
Teva’s long-acting schizophrenia drug rejected by FDA
Phil Taylor
MedinCell, Psychiatry, regulatory, schizophrenia, Teva
0 Comment
BioXcel gets first approval for agitation drug Igalmi
Phil Taylor
agitation, BioXcel, bipolar disorder, Igalmi, Psychiatry, regulatory approval, schizophrenia
0 Comment
AbbVie files Vraylar as add-on therapy for depression in US
Phil Taylor
AbbVie, depression, Psychiatry, regulatory, Vraylar
0 Comment
Sage, Biogen’s zuranolone looks approvable, but will it sell?
Phil Taylor
Biogen, depression, Psychiatry, Sage Therapeutics, zuranolone
0 Comment
Compass points to positive psilocybin trial, but shares fall
Phil Taylor
Compass Pathways, depression, psychedelics, Psychiatry
0 Comment
Biogen, Sage prep 2022 filing for depression drug zuranolone
Phil Taylor
Biogen, depression, fda, Psychiatry, Sage Therapeutics, zuranolone
0 Comment